PRAX
Praxis Precision Medicines Inc
NASDAQ: PRAX · HEALTHCARE · BIOTECHNOLOGY
$323.19
+0.39% today
Updated 2026-04-29
Market cap
$9.00B
P/E ratio
—
P/S ratio
953.14x
EPS (TTM)
$-13.47
Dividend yield
—
52W range
$35 – $356
Volume
0.4M
Praxis Precision Medicines Inc (PRAX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.46M | $2.45M | $8.55M | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | +67.1% | +249.5% | -100.0% |
| Cost of revenue | $1000.00 | $679000.00 | $746000.00 | $1.59M | $1.17M | $86.77M | $152.41M | $140000.00 |
| Gross profit | $-1000.00 | $-679000.00 | $-746000.00 | $-1.59M | $-1.17M | $-84.32M | $-143.86M | $-140000.00 |
| Gross margin | — | — | — | — | -80.0% | -3445.8% | -1682.0% | — |
| R&D | $18.82M | $29.56M | $44.98M | $120.26M | $155.04M | $86.77M | $152.41M | $267.12M |
| SG&A | $3.90M | $6.23M | $16.99M | $47.08M | $59.95M | $42.05M | $56.30M | $59.08M |
| Operating income | $-22.72M | $-35.79M | $-61.97M | $-167.33M | $-214.99M | $-126.37M | $-200.16M | $-326.20M |
| Operating margin | — | — | — | — | -14684.8% | -5164.4% | -2340.3% | — |
| EBITDA | $-26.27M | $-34.92M | $-61.92M | $-167.15M | $-214.57M | $-125.94M | $-199.81M | $-303.13M |
| EBITDA margin | — | — | — | — | -14656.2% | -5146.8% | -2336.1% | — |
| EBIT | $-26.27M | $-35.60M | $-61.97M | $-167.33M | $-214.99M | $-126.37M | $-200.16M | $-303.27M |
| Interest expense | $127000.00 | $0.00 | $190000.00 | $182000.00 | $419000.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-26.54M | $-35.51M | $-61.82M | $-166.88M | $-213.07M | $-123.28M | $-182.82M | $-303.27M |
| Net income growth (YoY) | — | -33.8% | -74.1% | -169.9% | -27.7% | +42.1% | -48.3% | -65.9% |
| Profit margin | — | — | — | — | -14554.1% | -5037.9% | -2137.5% | — |